AstraZeneca hit by falling Crestor sales, shares fall

LONDON (Reuters) – AstraZeneca’s first quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.

Source: Reuters Feed

(Visited 1 times, 1 visits today)

RSS Feed

Just a chill little widget delivery boy. =)

Leave a Reply

Your email address will not be published. Required fields are marked *